PubMed Health⌕ Search

PubMed · 16387572

Emergency department considerations regarding erectile dysfunction.

Abstract

The emergency department functions from a unique perspective. Often complex decisions must be made about patient management with incomplete information because of poor patient recall, lack of medical records, and no prior interactions with the patient being treated. Treatment decisions are often made before definitive diagnostic tests are performed and before complete historical information can be obtained. In general, emergency physicians will not prescribe treatment for routine clinical management of erectile dysfunction (ED). Conversely, the outpatient treatment of ED can impact treatment options available to the emergency physician when patients present with signs or symptoms of potential acute coronary syndromes (ACS). The emergency physician needs to have evidence-based guidance on how best to treat patients with potential ACS who are being treated for ED, how much time must elapse between the last dose of phosphodiesterase 5 (PDE5) inhibitor and treatment with nitrates, and how to modify treatment of patients with ACS when patients have recently used a PDE5 inhibitor. Additionally, patients who have been prescribed a PDE5 inhibitor should be educated on the use of nitrates and the need to inform physicians about the use of PDE5 inhibitors during all encounters so that risk can be minimized.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Judd E Hollander. 2005-11-15. Emergency department considerations regarding erectile dysfunction.. https://doi.org/10.1016/j.amjcard.2005.10.010

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.

Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, vardenafil, or tadalafil) or phosphorylation by cyclic nucleotide-dependent protein kinase causes an apparent conformational change in PDE5, as indicated by a shift in migration on non-denaturing PAGE gels and an altered pattern of tryptic digestion. Combination of cGMP and a PDE5 inhibitor or phosphorylation does not cause a further gel shift or change in tryptic digest. Phosphorylation of PDE5 is stimulated by inhibitors, and combination of cGMP and inhibitor does not cause further phosphorylation. Dephosphorylation of PDE5 by either purified phosphoprotein phosphatase-1 or -2A catalytic subunit or by a crude phosphatase mixture is not affected by cGMP or inhibitors, suggesting that phosphorylation itself maintains conformational exposure of the phosphorylation site. The combined results imply that cGMP binding to the catalytic site initiates negative feedback control of many cellular cGMP signaling pathways by directly stimulating phosphorylation and activation of PDE5; by exploiting this molecular mechanism, PDE5 inhibitors stimulate their own potencies.

3',5'-Cyclic-GMP Phosphodiesterases↗

Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.

The diagnosis and treatment of erectile dysfunction has changed dramatically since the availability of safe and effective oral therapies. Unfortunately, not all men can be adequately treated in this way, and might require more invasive testing to diagnose and treat the specific cause of their dysfunction. This review looks at the tests and strategies available for men who cannot be treated by oral therapy alone.

3',5'-Cyclic-GMP Phosphodiesterases↗